Evaluation of dopamine D3 receptor occupancy by blonanserin using [11C]-(+)-PHNO in schizophrenia patients
Authors:
Open Access
- 12 November 2020
- journal article
- research article
- Published by Springer Nature in Psychopharmacology
- Vol. 238 (5) , 1343-1350
Abstract
Rationale: Unlike other antipsychotics, our previous positron emission tomography (PET) study demonstrated that a single dose of blonanserin occupied dopamine D3 as well as dopamine D2 receptors in healthy subjects. However, there has been no study concerning the continued use of blonanserin. Objectives: We examined D2 and D3 receptor occupancies in patients with schizophrenia who had been treated with blonanserin. Methods: Thirteen patients with schizophrenia participated. PET examinations were performed on patients treated with clinical dosage of blonanserin or olanzapine alone. A crossover design was used in which seven patients switched drugs after the first scan, and PET examinations were conducted again. D2 and D3 receptor occupancies were evaluated by [11C]-(+)-PHNO. We used nondisplaceable binding potential (BPND) of 6 healthy subjects which we previously reported as baseline. To consider the effect of upregulation of D3 receptor by continued use of antipsychotics, D3 receptor occupancy by blonanserin in seven subjects who completed 2 PET scans were re-analyzed by using BPND of olanzapine condition as baseline. Results: Average occupancy by olanzapine (10.8 ± 6.0 mg/day) was as follows: caudate 32.8 ± 18.3%, putamen 26.3 ± 18.2%, globus pallidus − 33.7 ± 34.9%, substantia nigra − 112.8 ± 90.7%. Average occupancy by blonanserin (12.8 ± 5.6 mg/day) was as follows: caudate 61.0 ± 8.3%, putamen 55.5 ± 9.5%, globus pallidus 48.9 ± 12.4%, substantia nigra 34.0 ± 20.6%. EC50 was 0.30 ng/mL for D2 receptor for caudate and putamen (df = 19, p < 0.0001) and 0.70 ng/mL for D3 receptor for globus pallidus and substantia nigra (df = 19, p < 0.0001). EC50 for D3 receptor of blonanserin changed to 0.22 ng/mL (df = 13, p = 0.0041) when we used BPND of olanzapine condition as baseline. Conclusions: Our study confirmed that blonanserin occupied both D2 and D3 receptors in patients with schizophrenia.Keywords
This publication has 27 references indexed in Scilit:
- Effects of antipsychotics on D3 receptors: A clinical PET study in first episode antipsychotic naive patients with schizophrenia using [11C]-(+)-PHNOSchizophrenia Research, 2011
- Imaging dopamine receptors in humans with [11C]-(+)-PHNO: Dissection of D3 signal and anatomyNeuroImage, 2011
- Imaging Dopamine D3 Receptors in the Human Brain with Positron Emission Tomography, [11C]PHNO, and a Selective D3 Receptor AntagonistBiological Psychiatry, 2010
- The Antipsychotics Olanzapine, Risperidone, Clozapine, and Haloperidol Are D2-Selective Ex Vivo but Not In VitroNeuropsychopharmacology, 2010
- Blockade of [11C](+)-PHNO binding in human subjects by the dopamine D3 receptor antagonist ABT-925International Journal of Neuropsychopharmacology, 2009
- S33138 (N-[4-[2-[(3 aS,9 bR)-8-cyano-1,3 a,4,9 b-tetrahydro[1] benzopyrano[3,4-c]pyrrol-2(3 H)-yl)-ethyl]phenyl-acetamide), a Preferential Dopamine D3 versus D2 Receptor Antagonist and Potential Antipsychotic Agent: III. Actions in Models of Therapeutic Activity and Induction of Side EffectsThe Journal of Pharmacology and Experimental Therapeutics, 2008
- Consensus Nomenclature for in vivo Imaging of Reversibly Binding RadioligandsJournal of Cerebral Blood Flow & Metabolism, 2007
- Positron Emission Tomography Quantification of [11C]-(+)-PHNO Binding in the Human BrainJournal of Cerebral Blood Flow & Metabolism, 2007
- Behavioral Sensitization, Alternative Splicing, and D3 Dopamine Receptor-Mediated Inhibitory FunctionNeuropsychopharmacology, 2006
- Simplified Reference Tissue Model for PET Receptor StudiesNeuroImage, 1996